Search Results - "Berden, Floor A C"

Implementation of a decentralized hepatitis C care pathway for people who use drugs in Dutch addiction care. Study protocol for the Hepatitis C: chain of addiction care (CAC) project by Von den Hoff, Daan W, Berden, Floor A C, Drenth, Joost P H, Schellekens, Arnt F A

“…People who use drugs (PWUD) are at high risk for hepatitis C virus (HCV) infection and its complications. Given the high prevalence rate of HCV in PWUD, the…”
Get full text

Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study by Berden, Floor A C, de Knegt, Robert J, Blokzijl, Hans, Kuiken, Sjoerd D, van Erpecum, Karel J L, Willemse, Sophie B, den Hollander, Jan, van Vonderen, Marit G A, Friederich, Pieter, van Hoek, Bart, van Nieuwkerk, Carin M J, Drenth, Joost P H, Kievit, Wietske

“…Approval of drugs in chronic hepatitis C is supported by registration trials. These trials might have limited generalizability through use of strict…”
Get full text

If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs by Von den Hoff, Daan W., Berden, Floor A. C., Schellekens, Arnt F. A.

“…A recent meta-analysis collected all initiatives and categorised and compared according to level of decentralisation: no decentralisation; partial…”
Get full text

The ARRIBA concept: adequate resorption of ribavirin by de Kanter, Clara T M M, Koning, Ludi, Berden, Floor A C, Wasmuth, Jan-Christian, Grintjes-Huisman, Karin J T, Becker, Brigitta, Colbers, Angela P H, Roukens, Monique M B, Rockstroh, Jürgen K, Drenth, Joost P H, de Knegt, Robert J, Dofferhoff, Anton S M, Burger, David M

“…Adequate ribavirin exposure is essential for optimal sustained virological response (SVR) rates in chronic HCV treatment. It has been proposed that the area…”
Get more information

Identification of the Best Direct-acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: a Systematic Review and Network Meta-analysis by Berden, Floor A.C, Aaldering, Bryan R.R.Z, Groenewoud, Hans, IntHout, Joanna, Kievit, Wietske, Drenth, Joost P.H

“…Abstract Background & Aims Direct-acting antivirals (DAA) are effective in treatment of chronic hepatitis C virus (HCV) infection, although results for…”
Get full text

Against All Odds? Addiction History Associated with Better Viral Hepatitis Care: A Dutch Nationwide Claims Data Study by Von den Hoff, Daan W, Berden, Floor A C, Atsma, Femke, Schellekens, Arnt F A, Drenth, Joost P H

“…The elimination of viral hepatitis in target populations is crucial in reaching WHO viral hepatitis elimination goals. Several barriers for the treatment of…”
Get full text

High Risk of Infection During Triple Therapy with First-Generation Protease Inhibitors: A Nationwide Cohort Study by Berden, Floor A C, van Zwietering, Inke M J M, Maan, Raoel, de Knegt, Robert J, Kievit, Wietske, Drenth, Joost P H

“…Peginterferon (PegIFN) remains the backbone of therapy for chronic hepatitis C (CHC) in economically constrained regions. However, PegIFN may cause neutropenia…”
Get full text

The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions by Smolders, Elise J, Berden, Floor AC, de Kanter, Clara TMM, Kievit, Wietske, Drenth, Joost PH, Burger, David M

“…Background Direct-acting antivirals have improved treatment of chronic hepatitis C virus infection significantly. Direct-acting antivirals inhibit/induce and…”
Get full text

The Gap Between Registration Trials and Real World in Hepatitis C is Closing by Berden, Floor A.C, Vuik, Fanny E.R, Drenth, Joost P.H, Kievit, Wietske

Get full text